Table 2 Frequency distribution of first-line therapy
From: Temporal and geographic variation in the systemic treatment of advanced prostate cancer
Therapy/Year | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | All |
|---|---|---|---|---|---|---|---|
Docetaxel | 374 | 434 | 391 | 207 | 255 | 137 | 1798 |
97.1% | 66.0% | 48.9% | 22.6% | 24.4% | 29.0% | 42.1% | |
(95.0, 98.4) | (62.3, 69.5) | (45.4, 52.3) | (20.1, 25.5) | (21.9, 27.1) | (25.1, 33.2) | (40.6, 43.5) | |
Cabazitaxel | 7 | 9 | 7 | 3 | 4 | 3 | 33 |
1.8% | 1.4% | 0.9% | 0.3% | 0.4% | 0.6% | 0.8% | |
(0.9, 3.7) | (0.7, 2.6) | (0.4, 1.8) | (0.1, 1.0) | (0.1, 1.0) | (0.2, 1.8) | (0.6, 1.1) | |
Sipuleucel-T | 4 | 54 | 120 | 110 | 98 | 30 | 416 |
1.0% | 8.2% | 15.0% | 12.0% | 9.4% | 6.3% | 9.7% | |
(0.4, 2.6) | (6.3, 10.6) | (2.7, 17.6) | (10.1, 14.3) | (7.8, 11.3) | (4.5, 8.9) | (8.9, 10.7) | |
Radium-223 | 0 | 0 | 0 | 2 | 12 | 18 | 32 |
0.0% | 0.0% | 0.0% | 0.2% | 1.1% | 3.8% | 0.7% | |
(0.0, 1.0) | (0.0, 0.6) | (0.0, 0.5) | (0.1, 0.8) | (0.7, 2.0) | (2.4, 5.9) | (0.5, 1.1) | |
Abiraterone | 0 | 161 | 254 | 515 | 479 | 162 | 1571 |
0.0% | 24.5% | 31.8% | 56.3% | 45.8% | 34.2% | 36.7% | |
(0.0, 1.0) | (21.3, 27.9) | (28.6, 35.1) | (53.1, 59.5) | (42.8, 48.9) | (30.1, 38.6) | (35.3, 38.2) | |
Enzalutamide | 0 | 0 | 28 | 77 | 197 | 123 | 425 |
0.0% | 0.0% | 3.5% | 8.4% | 18.9% | 26.0% | 9.9% | |
(0.0, 1.0) | (0.0, 0.6) | (2.4, 5.0) | (6.8, 10.4) | (16.6, 21.3) | (22.3, 30.1) | (9.1, 10.9) | |
Total | 385 | 658 | 800 | 914 | 1045 | 473 | 4275 |